BeOne Highlights 78-Month BRUKINSA CLL Data At ASCO, Reports 71.8% Progression-Free Survival And Strong Sonrotoclax Combination Responses

شركة بيجين المحدودة

BeiGene Ltd ADR

ONC

0.00

BeOne Highlights 78-Month BRUKINSA CLL Data At ASCO, Reports 71.8% Progression-Free Survival And Strong Sonrotoclax Combination Responses